Stockscreener 앱 받기
126.17
1.85%
-2.525
전일 마감가:
$128.69
열려 있는:
$129.365
하루 거래량:
319.15K
Relative Volume:
0.22
시가총액:
$18.51B
수익:
$9.82B
순이익/손실:
$1.48B
주가수익비율:
12.45
EPS:
10.13
순현금흐름:
$2.30B
1주 성능:
-5.89%
1개월 성능:
-0.18%
6개월 성능:
-10.13%
1년 성능:
-43.92%
1일 변동 폭
$125.24
$129.58
1주일 범위
$125.24
$134.21
52주 변동 폭
$110.03
$236.48
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
BIIB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
126.31 | 19.83B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
773.58 | 709.79B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.53 | 379.41B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
190.29 | 344.45B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.07 | 244.38B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
64.61 | 315.52B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
What drives Biogen Inc. stock priceDynamic portfolio growth - Jammu Links News
Here's What To Expect From Biogen's Next Earnings Report - Barchart.com
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Edgestream Partners L.P. Sells 3,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Leo Wealth LLC - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Acquires 736,301 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire
Biogen’s Innovative Approach to SMA Treatment: The PIERRE-PK Study - TipRanks
Biogen’s Spinraza Study: Real-World Insights and Market Impact - TipRanks
Biogen’s New Study on MS Drug Vumerity: Key Insights for Investors - TipRanks
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection - TipRanks
Düsseldorf court to hear Tecfidera PI appeal as Biogen fights to stop generics - JUVE Patent
What is William Blair's Estimate for Biogen Q3 Earnings? - MarketBeat
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Biogen Inc. (NASDAQ:BIIB) Stock Position Reduced by Massachusetts Financial Services Co. MA - MarketBeat
Wedbush Forecasts Biogen's Q2 Earnings (NASDAQ:BIIB) - MarketBeat
Cwm LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
New York State Common Retirement Fund Acquires 20,130 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Alps Advisors Inc. Purchases Shares of 2,500 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cerity Partners LLC Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Biogen Executive Makes Significant Stock Sale - TipRanks
Insider Selling: Biogen Inc. (NASDAQ:BIIB) Insider Sells 2,223 Shares of Stock - MarketBeat
Brown Advisory Inc. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: Market Implications - TipRanks
Wedbush Forecasts Biogen's Q3 Earnings (NASDAQ:BIIB) - MarketBeat
Orphan Drugs Market Expansion Fueled by Rare Disease Research - openPR.com
William Blair Has Optimistic Outlook of Biogen Q2 Earnings - MarketBeat
Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com
State of Michigan Retirement System Has $5.43 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FY2025 EPS Estimates for Biogen Reduced by Leerink Partnrs - MarketBeat
Erythromelalgia Treatment Market Growing with Rare Disease - openPR.com
Wedbush Raises Price Target on Biogen to $129 From $121, Keeps Neutral Rating - MarketScreener
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors - GlobeNewswire Inc.
Biogen’s New Study on Omaveloxolone for Young FA Patients: Market Insights - TipRanks
SMN1 Gene Replacement Market 2025: Increasing SMA Population - openPR.com
Spinocerebellar Ataxias Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc, Biohaven Pharma - Barchart.com
Nisa Investment Advisors LLC Cuts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Holdings Cut by Greenleaf Trust - MarketBeat
M&T Bank Corp Has $1.68 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
When (BIIB) Moves Investors should Listen - news.stocktradersdaily.com
Banque Pictet & Cie SA Purchases 4,780 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Bank of New York Mellon Corp Decreases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Gene Therapy Market to Hit US$36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™ - Barchart.com
HSBC Raises Price Target on Biogen to $144 From $121, Maintains Hold Rating - MarketScreener
Biogen Inc.'s (NASDAQ:BIIB) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - 富途牛牛
JPMorgan maintains Neutral rating on Biogen stock amid gradual Leqembi ramp - Investing.com Nigeria
Case builds for Biogen, Stoke's Dravet syndrome drug - pharmaphorum
Allspring Global Investments Holdings LLC Has $1.43 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: A Market Game-Changer? - TipRanks
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - Insider Monkey
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
0.49%
자본화:
|
볼륨(24시간):